CN Patent

CN116600796A — 用于降低抑郁症患者的自杀风险的安非他酮和右美沙芬

Assigned to Antecip Bioventures II LLC · Expires 2023-08-15 · 3y expired

What this patent protects

本公开涉及一种治疗抑郁症和/或降低自杀风险的方法，包括施用约90mg至约120mg的氯化安非他酮(或摩尔当量的另一种形式的安非他酮)以及约40mg至约50mg的氢溴酸右美沙芬(或摩尔当量的另一种形式的右美沙芬)的组合。可以给患有严重抑郁症并在蒙哥马利‑奥斯堡抑郁症评定量表的自杀倾向项目(MADRS‑SI)上评分为3或更高的人每天施用两次该组合。

USPTO Abstract

本公开涉及一种治疗抑郁症和/或降低自杀风险的方法，包括施用约90mg至约120mg的氯化安非他酮(或摩尔当量的另一种形式的安非他酮)以及约40mg至约50mg的氢溴酸右美沙芬(或摩尔当量的另一种形式的右美沙芬)的组合。可以给患有严重抑郁症并在蒙哥马利‑奥斯堡抑郁症评定量表的自杀倾向项目(MADRS‑SI)上评分为3或更高的人每天施用两次该组合。

Drugs covered by this patent

Patent Metadata

Patent number: CN116600796A
Jurisdiction: CN
Classification: —
Expires: 2023-08-15
Drug substance claim: No
Drug product claim: No
Assignee: Antecip Bioventures II LLC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.